
USD
$0.00
(0.00%
)At Close (As of Nov 28, 2025)
$3.77B
Market Cap
125.55
P/E Ratio
0.38
EPS
$50.71
52 Week High
$22.61
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $298M |
| Total Revenue | $446M |
| Cost Of Revenue | $148M |
| Costof Goods And Services Sold | $148M |
| Operating Income | $16M |
| Selling General And Administrative | $178M |
| Research And Development | $69M |
| Operating Expenses | $282M |
| Investment Income Net | - |
| Net Interest Income | $11M |
| Interest Income | $11M |
| Interest Expense | $2K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $23M |
| Income Before Tax | $26M |
| Income Tax Expense | $1.6M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $24M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $26M |
| Ebitda | $49M |
| Net Income | $24M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $298M |
| Total Revenue | $446M |
| Cost Of Revenue | $148M |
| Costof Goods And Services Sold | $148M |
| Operating Income | $16M |
| Selling General And Administrative | $178M |
| Research And Development | $69M |
| Operating Expenses | $282M |
| Investment Income Net | - |
| Net Interest Income | $11M |
| Interest Income | $11M |
| Interest Expense | $2K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $23M |
| Income Before Tax | $26M |
| Income Tax Expense | $1.6M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $24M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $26M |
| Ebitda | $49M |
| Net Income | $24M |
Sector: HEALTHCARE
Industry: DIAGNOSTICS & RESEARCH
Veracyte, Inc. is a leading genomic diagnostics company headquartered in South San Francisco, California, specializing in innovative tests to improve patient care and diagnostic accuracy. With a focus on transforming the diagnosis of cancer and other diseases, Veracyte leverages its unique genomic technologies to provide actionable insights for clinicians and patients globally. The company is committed to expanding its comprehensive portfolio of diagnostic solutions, driving advancements in precision medicine, and enhancing patient outcomes through robust genomic testing.